Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H21NO3 |
Molecular Weight | 275.3428 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1OC2CCCC2)C3CNC(=O)C3
InChI
InChIKey=HJORMJIFDVBMOB-UHFFFAOYSA-N
InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)
Molecular Formula | C16H21NO3 |
Molecular Weight | 275.3428 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.depression-guide.com/rolipram.htmCurator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT00011375 | https://www.ncbi.nlm.nih.gov/pubmed/19776093 | https://www.ncbi.nlm.nih.gov/pubmed/1475038 | https://www.ncbi.nlm.nih.gov/pubmed/28202289
Sources: http://www.depression-guide.com/rolipram.htm
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT00011375 | https://www.ncbi.nlm.nih.gov/pubmed/19776093 | https://www.ncbi.nlm.nih.gov/pubmed/1475038 | https://www.ncbi.nlm.nih.gov/pubmed/28202289
Rolipram is a selective phosphodiesterase-4 inhibitor discovered and developed by Schering AG as a potential antidepressant drug in the early 1990s. Rolipram was discontinued after clinical trials showed that its therapeutic window was too narrow. Rolipram could not be dosed at high enough levels to be effective without causing significant gastrointestinal side effects. Rolipram promotes apoptosis in HL60 cells through a cAMP-independent mechanism and has been shown to enhance neuronal survival.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL254 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11052785 |
4.0 nM [IC50] | ||
Target ID: CHEMBL275 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18686943 |
20.0 nM [IC50] | ||
Target ID: CHEMBL288 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16263279 |
33.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. | 1991 |
|
Multiple second messenger systems act sequentially to mediate rolipram-induced prolongation of prostaglandin E2-induced mechanical hyperalgesia in the rat. | 1995 Feb |
|
Studies on anti-allergic action of AH 21-132, a novel isozyme-selective phosphodiesterase inhibitor in airways. | 1995 Feb |
|
Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. | 1995 Oct |
|
Delayed sympathectomy after a prolonged hyperalgesia results in a subsequent enhanced acute hyperalgesic response. | 1996 Apr |
|
Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. | 1996 Apr 1 |
|
Dipyridamole enhances interleukin-1beta-stimulated nitric oxide production by cultured rat vascular smooth muscle cells. | 1996 Feb 5 |
|
Action of cAMP on expression and release of adhesion molecules in human endothelial cells. | 1996 Mar |
|
The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation. | 1996 Nov |
|
Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. | 1997 May 19 |
|
Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT. | 1998 Jun |
|
Exogenous and endogenous catecholamines inhibit the production of macrophage inflammatory protein (MIP) 1 alpha via a beta adrenoceptor mediated mechanism. | 1998 Nov |
|
Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors. | 1998 Nov |
|
Pharmacological modulation of secondary mediator systems--cyclic AMP and cyclic GMP--on inflammatory hyperalgesia. | 1999 Jun |
|
The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. | 1999 May 21 |
|
beta-Adrenoceptor stimulation up-regulates phosphodiesterase 4 activity and reduces prostaglandin E2-inhibitory effects in human neutrophils. | 2000 Apr |
|
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models. | 2000 Aug |
|
Use of an activation-specific probe to show that Rap1A and Rap1B display different sensitivities to activation by forskolin in rat1 cells. | 2000 Jul 21 |
|
The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo. | 2001 Feb |
|
Endotoxin potentiation of trichothecene-induced lymphocyte apoptosis is mediated by up-regulation of glucocorticoids. | 2002 Apr 1 |
|
DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer. | 2002 Jun |
|
Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. | 2003 Aug 29 |
|
Rolipram, a specific type IV phosphodiesterase inhibitor, ameliorates indomethacin-induced gastric mucosal injury in rats. | 2003 May |
|
Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. | 2003 Sep |
|
Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. | 2004 Jun |
|
[Rolipram, a specific type IV phosphodiesterase inhibitor, ameliorates indomethacin-induced gastric mucosal injury in rats]. | 2004 Mar |
|
The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine 3',5'-monophosphate pathway in various cell types. | 2004 Nov |
|
Endothelins induce ETB receptor-mediated mechanical hypernociception in rat hindpaw: roles of cAMP and protein kinase C. | 2004 Oct 6 |
|
Global expression profiling of theophylline response genes in macrophages: evidence of airway anti-inflammatory regulation. | 2005 Aug 8 |
|
A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. | 2005 Jan 15 |
|
Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. | 2005 Mar 4 |
|
Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application. | 2006 Feb 17 |
|
ANP-mediated cGMP signaling and phosphodiesterase inhibition in the rat cervical spinal cord. | 2006 Jun |
|
Neuronal and smooth muscle receptors involved in the PACAP- and VIP-induced relaxations of the pig urinary bladder neck. | 2006 Sep |
|
The role of IFN-gamma in regulation of IFN-gamma-inducible protein 10 (IP-10) expression in lung epithelial cell and peripheral blood mononuclear cell co-cultures. | 2007 Nov 8 |
|
Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats. | 2008 |
|
Phosphodiesterase-4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (-)-adrenaline mediated through mouse cardiac beta(1)-adrenoceptors. | 2008 Feb |
|
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors. | 2008 Feb 15 |
|
Effect of phosphodiesterase type 4 inhibitor rolipram on cyclophosphamide-induced cystitis in rats. | 2008 May 31 |
|
Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats. | 2008 Oct |
|
Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach. | 2009 Dec |
|
Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats. | 2009 Jan |
|
Regulation of AMP-activated protein kinase by cAMP in adipocytes: roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis. | 2009 May |
|
Anti-inflammatory properties of Septilin in lipopolysaccharide activated monocytes and macrophage. | 2011 Mar |
|
Flavanoids induce expression of the suppressor of cytokine signalling 3 (SOCS3) gene and suppress IL-6-activated signal transducer and activator of transcription 3 (STAT3) activation in vascular endothelial cells. | 2013 Sep 1 |
|
Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network. | 2014 Apr 25 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19776093
Rolipram in Stage I were dosed up to 9 mg/day (3 mg, three times daily), patients in Stage II were dosed only up to 7.5 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28202289
The Glioblastoma cancer stem-like cells isolated from T2 at 5th passages having a purity of >95% based on the assessment of CD133 and CD15 expressions were harvested and seeded in 24-well plates containing DMEM-F12 at a density of 2.5 × 104 cells/well, overnight. The cells were treated with various concentrations (1, 3, 10, 30, 100 μg/ml) of bevacizumab (Roche, Switzerland) for 48 h. All treatments were done in quadruplicate. After finding of half maximal inhibitory concentration (IC50) of bevacizumab, the cells incubated with bevacizumab at IC50 in the absence or presence of rolipram (103 μM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:32:19 GMT 2023
by
admin
on
Fri Dec 15 15:32:19 GMT 2023
|
Record UNII |
K676NL63N7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
||
|
NCI_THESAURUS |
C744
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB10367MIG
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
4362
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
K676NL63N7
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL63
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
262-771-1
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
DTXSID3044124
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
D020889
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
m9650
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
5092
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
760125
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
85416-74-6
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
SUPERSEDED | |||
|
DB01954
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
61413-54-5
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
104872
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
100000084332
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
ROLIPRAM
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
40133
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY | |||
|
C72842
Created by
admin on Fri Dec 15 15:32:19 GMT 2023 , Edited by admin on Fri Dec 15 15:32:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
||
|
ENANTIOMER -> RACEMATE |
|
||
|
TARGET -> INHIBITOR |
Rolipram has good brain penetration, or an ability to pass the blood−brain barrier.
IC50
|
||
|
ENANTIOMER -> RACEMATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
BRAIN/PLASMA RATIO | PHARMACOKINETIC |
|
Species BIOLOGICAL PHARMACOKINETIC |
|
||